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Abstract
Background: Six-minute walk test (6MWT) is routinely performed in chronic thromboembolic pulmonary hypertension
(CTEPH) before pulmonary endarterectomy (PEA). However, the clinical relevance of heart rate response (ΔHR) and
exercise-induced oxygen desaturation (EID) during 6MWT is remaining unknown.
Methods: Patients undergoing PEA in our center between 03/2013-04/2014 were assessed prospectively with
hemodynamic and exercise parameters prior to and 1 year post-PEA. Patients with symptomatic chronic
thromboembolic disease (mean pulmonary artery pressure (mPAP) <25 mmHg) and clinical relevant obstructive
pulmonary disease were excluded. The following definitions were used: ΔHR = (peak HR - resting HR), percent heart
rate reserve (HRR) = (peak HR –rest HR)/(220 - age - rest HR) x 100 and EID = SpO2≤88 %.
Results: Thirty-seven patients (of 116 patients screened) with mPAP of 43.2 ± 8.7 mmHg, pulmonary vascular resistance
(PVR) of 605.5 ± 228.7 dyn*s/cm5, cardiac index (CI) of 2.4 ± 0.5 l/min/m2 and a 6MWT-distance of 404.7 ± 148.4 m and
a peak VO2 of 12.3 ± 3.4 ml/min/kg prior to PEA were included. Baseline ΔHR during 6MWT was significantly associated
with PVR 1 year post-PEA using linear regression analysis (r = 0.43, p = 0.01). Multivariate analysis indicated an
association of HRR during 6MWT and residual PH with a hazard ratio of 1.06 (95 % Confidence interval for
hazard ratio 0.99–1.14, p = 0.08). EID was observed commonly during 6MWT but no correlations to outcome
parameters were found.
Conclusions: This is the first prospective study to describe an association of ΔHR during 6MWT with pulmonary
hemodynamics 1 year post-PEA. Our preliminary results indicate that HRR derived from 6MWT is of clinical
significance. EID was commonly observed, albeit failed as a significant prognostic factor.
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Background
Chronic thromboembolic pulmonary hypertension
(CTEPH) is defined by an elevation of mean pulmonary
arterial pressure (mPAP) and pulmonary vascular resist-
ance (PVR) caused by unresolved pulmonary vascular ob-
struction due to recurrent embolism [1, 2]. Mechanical
obstruction in proximal parts of the pulmonary vascular
system and secondary small-vessel arteriopathy in the
non-obstructed areas are causes of disease progression
and lead to extensive right ventricle (RV) dysfunction,
loading and failure [1, 2]. Pulmonary endarterectomy
(PEA) is the gold standard in case of surgical accessible
CTEPH and offers a potential curative treatment with an
improved functional outcome and high survival rates
[3, 4]. Predictors of favorable outcome after PEA are
important in daily clinical practice and include pre-
operative forced expiratory volume in 1 s (FEV1),
heart-type fatty acid-binding protein (H-FABP) and car-
diac index (CI) [5, 6]. In addition, 6-minute walk testing
(6MWT) with measurement of the distance covered
(6MWD) is performed routinely before and after PEA
as a tool to assess disease severity, functional capacity
or long-term outcome [7, 8]. Moreover, preoperative
6MWD correlates with 3-month survival after PEA [9].
However, the prognostic relevance of additional parameters
derived from the 6MWT were not evaluated in detail be-
fore. Presently, it is unknown whether exercise-induced
oxygen desaturation (EID) or heart rate response (ΔHR)
during 6MWD associate with disease severity, functional
or hemodynamic outcome in operable CTEPH. Neverthe-
less, patients with CTEPH frequently display significant
EID with inadequate increase in heart rate (HR) during
exercise [10]. Previously, EID has been related to reduced
exercise performance and increased mortality in patients
with chronic obstructive pulmonary disease (COPD) and
pulmonary fibrosis [11, 12], whereas ΔHR in pulmonary
arterial hypertension (PAH) was analyzed in the context of
baseline exercise capacity and functional improvements
under targeted therapy [13]. Furthermore, chronotropic
incompetence derived from heart rate reserve (HRR) was
identified as an important and independent predictor of
mortality in population based studies [14]. Moreover, pa-
rameters such as peak oxygen uptake (VO2), peak systolic
and diastolic blood pressure derived from cardio pulmon-
ary exercise testing (CPET) are better correlated with func-
tional class and prognosis than resting hemodynamic
parameters in PAH [15]. So far, the significance of ΔHR
and EID during 6MWD in comparison to CPET is
remaining unknown in CTEPH.
We hypothesized that EID during 6MWD in CTEPH
might be of prognostic relevance and related to the ex-
tent of dyspnea. Moreover, we speculated that the ΔHR
derived from the 6MWT reflects the inappropriate re-
sponse of the RV with insufficient increase of the cardiac
output (CO) to exercise, as it was shown for CPET
[16]. Therefore, our aim was to prospectively investi-
gate ΔHR and EID during 6MWT in patients with
operable CTEPH and their associations with clinical
symptoms and hemodynamic outcome 1 year post-
PEA. In addition, we aim to compare ΔHR and EID
assessed during 6MWT with CPET prior PEA in re-
gard of their predictive significance.
Methods
Patients
All CTEPH patients undergoing PEA between March
2013 and April 2014 at the Department of Thoracic
surgery, Kerckhoff-Clinic, Bad Nauheim, Germany were
prospectively screened. After exclusion, 67 patients en-
tered the study pre-PEA, while only patients with
complete baseline and 1 year post-PEA hemodynamic
data were analyzed (n = 37) (Fig. 1). Baseline and follow-
up right heart catheter (RHC) were not mandatorily per-
formed in-house, as the Kerckhoff-Clinic is a national
referral center. Patients with symptomatic chronic
thromboembolic disease (mean pulmonary artery pres-
sure <25 mmHg at baseline [17]), obstructive pulmonary
disease (forced expiratory volume in 1 s/vital capacity
(FEV1/VC) ≤70 %) were excluded.
CTEPH was diagnosed according to current guidelines
[18] and operability was assessed by a multidisciplinary
board including pulmonary physicians, PEA surgeons
and pulmonary radiologists. All patients received oral
anticoagulants for at least 3 months and underwent PEA
according to the protocol of the Kerckhoff-Clinic [19].
Residual PH 1 year post-PEA were defined by mPAP
>25 mmHg and PVR >240 dyn*s/cm5 at rest [20] while
CTEPH type was classified by the surgical specimen as
described previously [21].
All included patients gave written, informed consent,
and the study was approved by the by the ethics com-
mittee of the Faculty of Medicine at the University of
Giessen (Approval No. 67/14).
The following definitions were used: ΔHR= (peak HR -
resting HR) [22], HRR = (peak HR –rest HR)/(220 - age -
rest HR) x 100 [23] and EID = oxygen pulse saturation
(SpO2) ≤88 % [12, 24].
6-minute walk test
All patients performed 6MWT at the Kerckhoff-Clinic ac-
cording to current guidelines [25]. Patients were instructed
to walk at their own pace while standard phrases were
communicated [25]. HR and oxygen pulse saturation
(SpO2) using pulse oximetry (Oximax™, N-65™, Covidien
AG, USA) were measured at baseline and every minute
until minute 6. In addition, patients were asked to quantify
their sensation of dyspnea with the BORG scale [26]. As
described previously, the respiratory therapist checked that
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the pulse oximeter had an acceptable signal before be-
ginning all tests and carefully instructed the patient
[12]. Patients already receiving supplemental oxygen at
rest performed 6MWT with their current oxygen dos-
age. 6MWD was defined as the maximal achieved walk
distance in m at room air or oxygen-supplemented.
Cardio-pulmonary exercise testing
Prior PEA patients performed a symptom-limited incre-
mental CPET using a ramp protocol with an incremental
rate of 5 to 15 W/min judged by the operator (Mastersc-
reen CPX®, Carefusion®), according to current recommen-
dations [27]. Patients receiving supplemental oxygen and
exhibited a resting SpO2 less than 88 % were excluded. Pa-
tients were asked to exercise up to their individual limit,
while exercise was terminated due to exercise-limiting
symptoms by the patient. Dead space ventilation (VD/VT)
was calculated using the Bohr- formula, while absolute
dead space (VD) was assessed in milliliters [28].
Baseline parameters
Hemodynamic, laboratory, echocardiography data were col-
lected before and after PEA in all included patients. Right
heart echocardiography assessed pulmonary artery systolic
pressure (PASP) and tricuspid annular plane systolic excur-
sion (TAPSE) according to current recommendations [29].
Statistical analysis
Data are presented as mean ± standard deviation (SD) for
normally distributed parameters or median [interquartile
range (IQR)]. As appropriate the 2-tailed T-test, paired T-
test, Wilcoxon Signed Rank test, Mann-Whitney-U-test
or Pearson Chi-Square test was used to test for differences
between groups. Linear regression analysis was performed
between follow-up hemodynamic parameters and baseline
6MWT and CPET characteristics. In addition, all baseline
parameters were analyzed univariate in a logistic regres-
sion model with residual PH as dependent variable.
Then all parameters of the univariate analysis with a
p-value < 0.15, were entered into a backward stepwise
multivariate logistic regression model to predict residual
PH 1 year post-PEA. P-value of < 0.10 was considered
statistically significant in the multivariate analyses. Statis-
tical analysis was performed using SPSS, version 21.0
(IBM, Armonk, NY).
Results
Baseline
Thirty-seven CTEPH patients with a mean age of 61 ±
12 years and a body mass index of 27.9 ± 5.8 kg/m2
mostly in WHO functional class III were included. Pa-
tients showed impaired pulmonary hemodynamics with
a precapillary pattern, substantially reduced CI and ele-
vated PVR before PEA. Concomitant right heart echo-
cardiography showed an elevated PASP and a reduced
TAPSE. Lung function testing revealed no significant
obstructive or restrictive ventilatory abnormalities. Dur-
ing 6MWT peak SpO2 decreased to 88.8 ± 5.6 % with a
Δ SpO2 of - 5.1 ± 4.4 %, HR increased to a mean peak of
117.1 ± 18.8 beats*min−1 while ΔHR was 32.6 ± 14.7
Fig. 1 Flow chart of patient selection. RHC: right heart catheterization, PEA: pulmonary endarterectomy, PH: pulmonary hypertension
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Table 1 Baseline characteristics
Baseline One year post-PEA p-value
Patients, n 37
Male/female 20/17
Age (y) 61 ± 12
BMI (kg/m2) 27.9 ± 5.8
WHO functional class, (%) b 0.7
I none 29.6
II 27 48.1
III 62.2 22.2
IV 10.8 None
6MWT
6MWD (m) 404.7 ± 148.4 453.4 ± 126.8 0.1
Rest SpO2 (%) 93.9 ± 2.7 95.6 ± 2.9 0.043
Peak SpO2 (%) 88.8 ± 5.6 92.2 ± 4.5 0.003
Δ SpO2 (%) −5.1 ± 4.4 −3.5 ± 4.1 0.15
Rest HR (beatsbmin-1) 83.8 ± 14.4 83.5 ± 13.9 0.98
Peak HR (beatsbmin-1) 117.1 ± 18.8 107.8 ± 17.1 0.041
Δ HR (beatsbmin-1) 32.6 ± 14.7 24.3 ± 12.9 0.038
HRR (%) 45.1 ± 20.6 33.4 ± 16.7 0.022
Δ Borg 4.4 ± 2.2 3.1 ± 2.4 0.006
Supplemental Oxygen (n, %) 9 (24.3) 3 (8.1)b 0.33
Lung function
FEV1 (% pred.) 88.7 ± 13.8 88.2 ± 12.5 0.76
FEV1/FVC (% pred.) 96 ± 10.3 90.6 ± 12.1 0.05
TLC (% pred.) 99 ± 13.5 104.8 ± 16.8 0.11
VC (% pred.) 91.6 ± 13.7 94 ± 12.7 0.34
RHC
mPAP (mm Hg) 43.2 ± 8.7 28.9 ± 10.1 0.001
RAP (mm Hg) 5.9 ± 4.1 7.2 ± 4.3 0.15
PVR (dynebs/cm5) 605.5 ± 228.7 328.1 ± 241.4 0.001
CI (l/min/m2) 2.4 ± 0.5 2.7 ± 1.3 0.048
PAWP (mm Hg) 9.5 ± 4.6 10.6 ± 4.5 0.19
Echocardiography
TAPSE (mm) 17.2 ± 4.3 17.5 ± 3.2 0.62
PASP (mm Hg) 69.8 ± 25.1 56.8 ± 23.7 0.041
CPETc
Peak VO2 (ml/min/kg) 12.3 ± 3.4 14.2 ± 4.2 0.33
Rest VD/VT 35.2 ± 7.6 32 ± 5.8 0.77
Peak VD/VT 39.5 ± 8.7 35 ± 11.9 0.6
Rest VD, L 0.35 ± 0.17 0.29 ± 0.11 0.39
Peak VD, L 0.65 ± 0.25 0.72 ± 0.21 0.55
Rest SpO2 (%) 94.2 ± 1.7 95.1 ± 1.4 0.10
Peak SpO2 (%) 89.3 ± 1.4 90.7 ± 4.8 0.86
Δ SpO2 (%) −4.9 ± 5.8 −4.4 ± 4.3 0.69
Rest HR (beatsbmin-1) 72.8 ± 12.2 81.2 ± 11.2 0.15
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beats*min−1 and HRR was 45.1 ± 20.6 %. Sensation of dys-
pnea as assessed by the BORG score showed a substantial
increase (Δ BORG 4.4 ± 2.2). In total, 9 patients under-
went the 6MWT with supplemental oxygen (Table 1). In
total, 34 patients performed CPET displaying an impaired
exercise capacity while VD and VD/VT exhibited a signifi-
cant increase during exercise. During CPET peak SpO2
decreased to 89.3 ± 1.4 % with a ΔSpO2 of - 4.9 ± 5.8 %,
HR increased to a mean peak of 120.7 ± 21.3 beats*min−1
while ΔHR was 47.9 ± 19.4 beats*min−1 and HRR was
54.7 ± 22.1 %.
One year post-PEA
Hemodynamic and functional parameters significantly
improved 1 year post-PEA as compared to baseline.
Patients presented mostly in WHO functional class I
and II, resting and peak SpO2 were significantly higher
during 6MWT and peak HR, ΔHR and HRR and NT-
proBNP were significantly lower 1 year post-PEA. A
trend towards decrease was observed in resting VD/VT
and VD during CPET (Table 1). In total, 21 patients pre-
sented with residual PH displaying significantly elevated
mPAP, PVR, NT-proBNP and reduced CI in comparison
with non-residual PH. In addition, patients with residual
PH presented to a higher degree in WHO functional
class III and showed, in comparison with non-residual
PH, a significant lower rest and peak SpO2 during
6MWT. HRR was significantly higher in patients with
residual PH while ΔHR showed a trend to higher values.
Dyspnea as measured by BORG score was significantly
increased in patients with residual PH, while the admin-
istration of supplemental oxygen did not differ between
groups (Table 2). In comparison with non-residual PH
no significant differences of peak VO2, SpO2, HR or
HHR derived from CPET were shown.
Clinical relevance of exercise-induced oxygen desaturation
Baseline characteristics were analyzed according to
the presence of EID during 6MWT, while pulmonary
hemodynamics, exercise capacity, VD/VT and Jamieson-
Type showed no significant differences in comparison.
Interestingly, 12 out of 37 patients exhibited EID with a
ΔSpO2 of 10 ± 1.1 % (Table 3), while a rapid continuous
desaturation was evident already starting at minute
one of the 6MWT (Fig. 2a). BORG score at minute 3
was significantly higher in patients with EID, albeit
ΔBORG and peak BORG score showed a trend to higher
values in EID (Fig. 2b).
There were no significant associations between rest
SpO2, peak SpO2 or ΔSpO2 with hemodynamic or func-
tional parameters 1 year post-PEA during 6MWT and
CPET (data not shown).
Univariate logistic regression analysis revealed that
baseline peak SpO2 or Δ SpO2 during 6MWT were not
associated with the presence of residual PH. Univariate
analysis related rest SpO2 during 6MWT to residual PH
with a hazard ratio of 0.8 (95 % Confidence interval for
hazard ratio 0.6–1.06, p = 0.11). However, additional
stepwise backward multivariate analysis showed that rest
SpO2 derived from 6MWT was not independently asso-
ciated with the hemodynamic outcome 1 year post-PEA.
In addition, rest SpO2, peak SpO2 or ΔSpO2 derived
from CPET failed as prognostic markers using univariate
analysis (Table 4).
Table 1 Baseline characteristics (Continued)
Peak HR (beatsbmin-1) 120.7 ± 21.3 122.9 ± 19.6 0.25
Δ HR (beatsbmin-1) 47.9 ± 19.4 41.7 ± 16.3 0.72
HRR (%) 54.7 ± 21.1 53.7 ± 20.2 0.92
Co-morbidities, n (%)
Hypertension 24 (64.9) Unchanged
Coronary heart disease 4 (10.8) Unchanged
Renal insuffiency 4 (10.8) Unchanged
Jamieson-Type, %
I 31
II 31
III 38
Laboratory
NT-proBNP (pg/ml) 488.2 [1004] 245.0 [422]a 0.006
Values represent mean ± SD or median [IQR]. pred.: predicted, a = Wilcoxon Signed Rank test, b = Pearson Chi-Square test, cn = 34. CI cardiac index, mPAP mean
pulmonary arterial pressure, PVR pulmonary vascular resistance, RAP right atrial pressure, PAWP pulmonary arterial wedge pressure, TAPSE tricuspid annular plane
systolic excursion, PASP pulmonary artery systolic pressure, 6MWD six-minute walking distance, VO2 oxygen uptake, WHO World Health Organization, NT-proBNP
N-terminal fragment of pro-brain natriuretic peptide, VD absolute dead space, VD/VT dead space ventilation, HR heart rate, SpO2 oxygen pulse saturation, RHC right
heart catheter, CPET cardio-pulmonary exercise testing, HRR heart rate reserve, VC vital capacity, FRC functional residual capacity, TLC total lung capacity, FEV1
forced expiratory volume in 1 s
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Clinical relevance of heart rate response
During 6MWT an initial steep and then flattened HR
response was observed (Fig. 2a). Baseline ΔHR during
6MWT was significantly associated with PVR 1 year post-
PEA (r = 0.43, p = 0.01) (Fig. 3a). However, using linear re-
gression analysis ΔHR showed no significant associations
with mPAP (Fig. 3b) or other pulmonary hemodynamic
parameters 1 year post-PEA (data not shown). There were
no significant associations of rest HR, peak HR or HRR
with hemodynamic parameters 1 year post-PEA (data not
shown). Interestingly, HR parameters derived from
CPET were not significantly associated with hemodynamic
parameters 1 year post-PEA (data not shown).
Univariate logistic regression analysis revealed that
baseline ΔHR and HRR during 6MWT were significantly
associated with the presence of residual PH. The step-
wise backward multivariate model associated HRR and
Jamieson-Type with the hemodynamic outcome 1 year
post-PEA. Intriguingly, no such association were found
for the Δ HR or HRR during CPET (Table 4).
Discussion
In the current study we could show for the first time
that additional characteristics derived from 6MWT in
operable CTEPH were of clinical relevance. The novel
findings of the present study include 1) that EID during
6MWT is commonly observed in operable CTEPH pre-
PEA, and 2) baseline HRR, but not EID, during 6MWT
is associated with the hemodynamic outcome 1 year
post-PEA. To the best of our knowledge, this is the first
study that evaluated specific characteristics from
6MWT in a selected cohort of operable CTEPH patients
and demonstrated their impact on the hemodynamic out-
come post-PEA.
CTEPH patients with reduced exercise capacity, mostly
in WHO functional class III and severely impaired pulmon-
ary hemodynamics prior PEA were prospectively included.
Our cohort demonstrated the typical precapillary PH pat-
tern with significant impairment of RV function resulting in
Table 2 Parameters 1 year post-PEA according to non-residual
and residual PH
Non-residual
PH
Residual PH p-
value
Patients, n (%) 16 (43.2) 21 (56.8)
WHO functional class, (%) a 0.002
I 46.2 None
II 53.8 57.1
III None 42.9
IV None None
6MWT
6MWD (m) 487.6 ± 72.1 432.4 ± 148.9 0.26
Rest SpO2 (%) 97 ± 1.9 94.8 ± 3.1 0.05
Peak SpO2 (%) 94.3 ± 4.4 90.8 ± 4.1 0.05
Δ SpO2 (%) −2.7 ± 3.8 −3.9 ± 4.4 0.47
Rest HR (beatsamin-1) 83.9 ± 15.1 83.2 ± 13.9 0.9
Peak HR (beatsamin-1) 101.6 ± 15.2 111.5 ± 17.6 0.2
Δ HR (beatsamin-1) 17.8 ± 6.3 28.3 ± 14.4 0.06
HRR (%) 24.3 ± 11.5 28.3 ± 14.4 0.05
Δ Borg 1.7 ± 1.9 3.9 ± 2.4 0.02
Supplemental Oxygen (n,
%)
1 (6.3) 2 (9.5) -
Lung function
FEV1 (% pred.) 93.9 ± 12.8 83.9 ± 10.6 0.02
FEV1/FVC (% pred.) 95.8 ± 13.9 86.7 ± 9.2 0.03
TLC (% pred.) 104.2 ± 15.2 105.2 ± 18.3 0.87
VC (% pred.) 96.8 ± 14.0 92.1 ± 11.6 0.3
RHC
mPAP (mm Hg) 19.7 ± 3.2 36 ± 7.5 0.001
RAP (mm Hg) 5.5 ± 2.4 8.7 ± 5.1 0.04
PVR (dyneas/cm5) 218.3 ± 280.9 415.9 ± 163.7 0.012
CI (l/min/m2) 2.9 ± 0.4 2.6 ± 0.6 0.09
PAWP (mm Hg) 8.9 ± 3.8 12.2 ± 4.7 0.037
Echocardiography
TAPSE (mm) 18.3 ± 2.7 16.7 ± 3.6 0.2
PASP (mm Hg) 50.6 ± 29.2 59.5 ± 21.9 0.5
CPETb
Peak VO2 (ml/min/kg) 15.2 ± 4.5 13.3 ± 3.9 0.36
Rest VD/VT 30.3 ± 5.1 35.3 ± 6.4 0.35
Peak VD/VT 27.7 ± 6.1 41.2 ± 12.1 0.13
Rest VD, L 0.22 ± 0.07 0.37 ± 0.09 0.09
Peak VD, L 0.63 ± 0.1 0.78 ± 0.26 0.39
Rest SpO2 (%) 95.1 ± 1.3 93.7 ± 1.8 0.10
Peak SpO2 (%) 89.1 ± 7.3 89.6 ± 4.6 0.86
Δ SpO2 (%) −5.2 ± 5.4 −3.6 ± 3.3 0.69
Rest HR (beatsamin-1) 76.1 ± 12.4 69.9 ± 11.7 0.15
Peak HR (beatsamin-1) 125.3 ± 22.4 116.6 ± 19.9 0.25
Table 2 Parameters 1 year post-PEA according to non-residual
and residual PH (Continued)
Δ HR (beatsamin-1) 49.2 ± 19.3 46.7 ± 19.9 0.72
HRR (%) 55.1 ± 21.1 54.3 ± 21.8 0.92
Jamieson-Type, (%) a 0.15
I 14.2 46.7
II 42.9 20
III 42.9 33.3
Laboratory
NT-proBNP (pg/ml) 175.0 [56–259] 389.0 [95–
703]
0.18
Values represent mean ± SD or median [IQR]. a = Pearson Chi-Square test,
bn = 34. For abbreviations see Table 1
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Table 3 Parameters at baseline according to exercise-induced oxygen desaturation during 6MWT
Baseline
EID Non-EID p-value
Patients, n (%) 12 (32.4) 25 (67.6)
WHO functional class, (%) a 0.09
II 33.3 24
III 41.7 72
IV 25 4
6MWT
6MWD (m) 448.9 ± 206.8 383.6 ± 109.5 0.22
Rest SpO2 (%) 92.0 ± 2.2 94.8 ± 2.1 0.002
Peak SpO2 (%) 81.9 ± 4.4 92.1 ± 2.3 0.001
Δ SpO2 (%) 10.0 ± 1.1 2.7 ± 0.4 0.02
Rest HR (beatsamin-1) 83.5 ± 16.4 84 ± 13.7 0.9
Peak HR (beatsamin-1) 120.6 ± 20.7 115.5 ± 18.1 0.45
Δ HR (beatsamin-1) 30.5 ± 5.1 30.4 ± 2.4 0.82
HRR (%) 49.5 ± 8.1 42.5 ± 4 0.53
Δ Borg 4.7 ± 0.7 4.3 ± 0.5 0.52
Supplemental Oxygen (n, %) 4 (33.3) 5 (20) a 0.38
Lung function
FEV1 (% pred.) 83.6 ± 11.9 90.9 ± 14.1 0.15
FEV1/FVC (% pred.) 98.6 ± 10.2 94.8 ± 10.3 0.31
TLC (% pred.) 94.8 ± 16.3 100.8 ± 12.1 0.24
VC (% pred.) 85.8 ± 10.3 94.1 ± 14.4 0.1
RHC
mPAP (mm Hg) 43.8 ± 8.2 42.9 ± 9.0 0.77
RAP (mm Hg) 4.1 ± 2.7 6.6 ± 4.4 0.8
PVR (dyneas/cm5) 640.1 ± 231.0 587.4 ± 230.5 0.53
CI (l/min/m2) 2.5 ± 0.6 2.4 ± 0.5 0.7
PAWP (mm Hg) 9.3 ± 2.8 9.7 ± 5.4 0.8
Echocardiography
TAPSE (mm) 16.6 ± 4.3 17.4 ± 4.3 0.63
PASP (mm Hg) 77.2 ± 30.7 66.2 ± 21.7 0.24
CPETc
Peak VO2 (ml/min/kg) 13.1 ± 1.3 12.1 ± 0.6 0.65
Rest VD/VT 33.0 ± 7.3 36.0 ± 8 0.48
Peak VD/VT 39.0 ± 12.0 40.0 ± 7.3 0.78
Rest VD, L 0.41 ± 0.22 0.34 ± 0.14 0.4
Peak VD, L 0.67 ± 0.33 0.65 ± 0.23 0.9
Jamieson-Type, (%) a 0.72
I 25 32
II 50 26
III 25 42
Laboratory
NT-proBNP (pg/ml) 414.0 [1260.2] 836.7 [1521]b 0.71
Values represent mean ± SD or median [IQR]. a = Pearson Chi-Square test, b = Mann-Whitney U Test, cn = 34.; For abbreviations see Table 1
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a reduced CI, elevated PVR and mPAP [7, 30–33].
Hemodynamic parameters and exercise capacity substan-
tially improved 1 year post-PEA, albeit 21 patients
(56.8 %) presented with a residual PH. In total, a signifi-
cant improvement of the functional outcome 1 year
post-PEA was observed as described previously [3, 4].
However, the high rate of residual PH in our selected
cohort underlined that the individual outcome post-
PEA differed while rates of residual PH up to 35 % were
previously reported [20, 32, 34].
Our results describe for the first time that after exclusion
of obstructive pulmonary diseases, almost ~32 % of oper-
able CTEPH exhibited a substantial EID during 6MWT
prior to PEA. Further, these patients reported an enhanced,
albeit not significant, increased sensation of dyspnea dur-
ing 6MWT. Our data support the high prevalence of EID
Fig. 2 a Heart rate (HR) and SpO2 during 6MWT according to exercise-induced oxygen desaturation (EID). Data are presented as mean ± standard
error of means. **p = 0.002, †p < 0.001 versus non-EID. (black line = EID; grey line = non-EID; ▲= SpO2; ●= HR). b BORG score during 6MWT
according to exercise-induced oxygen desaturation (EID). Data are presented as mean ± standard error of means. *p = 0.02 versus non-EID.
(black line = EID; grey line = non-EID)
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during 6MWT in CTEPH as described previously in a
heterogeneous group of PH patients [35]. Furthermore, pa-
tients with residual PH showed significantly higher BORG
scores and lower peak SpO2-levels 1 year post-PEA. The
cause of EID and sensation of dyspnea is multifactorial in
CTEPH, including gas exchange abnormalities with exer-
tional hypoxaemia due to increased VD/VT and V/Q mis-
match, increased chemosensitivity as a stimulus of exercise
hyperventilation and insufficient enhancement of CO due
to RV dysfunction [16, 28, 36]. One can speculate that
ventilatory inefficiency with an increased VD/VT during ex-
ercise due to increased V/Q mismatch results in EID,
which however couldn’t be extrapolated by our data as sig-
nificant correlations between EID and VD/VT were lacking.
The absence of significant associations between EID and
VD/VT might be related to the relatively small increase in
VD/VT during exercise observed in our cohort, as previ-
ously peak VD/VT up to 50 were reported [36]. In addition,
Table 4 Baseline parameters as predictors of residual PH 1 year post PEA
Univariate model Multivariate model*
Hazard ratio (95 % confidence interval) p-value Hazard ratio (95 % confidence interval) p-value
6MWT
6MWD (m) 1.01 [0.99–1.01] 0.44 - -
Rest SpO2 (%) 1.25 [0.94–1.67] 0.11 - -
Peak SpO2 (%) 0.96 [0.85–1.08] 0.46 - -
Δ SpO2 (%) 0.99 [0.86–1.16] 0.96 - -
Rest HR (beats*min-1) 0.99 [0.94–1.03] 0.6 - -
Peak HR (beats*min-1) 1.03 [0.99–1.06] 0.19 - -
Δ HR (beats*min-1) 1.10 [1.03–1.2] 0.009 - -
HRR (%) 1.06 [1.02–1.1] 0.01 1.06 [0.99–1.14] 0.08
CPET
Rest SpO2 (%) 1.81 [0.86–3.76] 0.12 - -
Peak SpO2 (%) 1.02 [0.86–1.20] 0.84 - -
Δ SpO2 (%) 1.05 [0.86–1.27] 0.66 - -
Rest HR (beats*min-1) 0.96 [0.90–1.02] 0.16 - -
Peak HR (beats*min-1) 0.98 [0.95–1.01] 0.25 - -
Δ HR (beats*min-1) 0.99 [0.96–1.03] 0.71 - -
HRR (%) 1.00 [0.97–1.03] 0.91 - -
Peak VO2 (ml/min/kg) 0.95 [0.78–1.17] 0.63 - -
RHC
mPAP (mm Hg) 1.07 [0.98–1.16] 0.13 - -
RAP (mm Hg) 1.01 [0.83–1.2] 0.96 - -
PVR (dyne*s/cm5) 1.01 [0.99–1.01] 0.19 - -
CI (l/min/m2) 1.10 [0.3–4.01] 0.89 - -
PAWP (mm Hg) 1.03 [0.89–1.2] 0.67 - -
Echocardiography
TAPSE (mm) 0.90 [0.77–1.06] 0.2 - -
PASP (mm Hg) 1.03 [0.99–1.07] 0.06 - -
Other
Nt-pro BNP (pg/ml) 1.00 [0.99–1.01] 0.97 - -
WHO functional class - 0.39 - -
Jamieson-Type
• I Reference Reference
• II 4.2 [0.6–30.1] 0.15 8.9 [0.7–116.4] 0.096
• III 1.67 [0.28–3.57] 0.58 5.02 [3.23–100] 0.25
For abbreviations see Table 1. *: backward stepwise logistic regression including variables with a p-value <0.15 in the univariate model
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baseline resting VD/VT was lower than previously reported
indicating that pulmonary perfusion was, overall, slightly
better in our cohort [30]. Surprisingly, baseline EID was
neither associated with hemodynamic parameters 1 year
post-PEA nor with the presence of residual PH. Therefore
our data emphasized that baseline EID failed as a surrogate
marker to predict small-vessel arteriopathy, non-removable
material or impaired RV reverse remodeling post-PEA
which were identified as major causes of residual PH [20].
Nevertheless, EID was described as a powerful prognostic
marker of overall survival in PAH, pulmonary fibrosis or
COPD previously [11, 12, 37]. In addition, SpO2-levels or
EID derived from CPET failed as relevant prognostic
factors in our multivariate model.
Interestingly, our data indicated for the first time that
ΔHR prior PEA was related to PVR 1 year post-PEA in
operable CTEPH patients. In addition, HRR during
6MWT was associated with the presence of residual PH.
Even though the association of an enhanced baseline
HRR with the presence of residual PH might look para-
doxical at first sight, its’ pathophysiologic meaning in
CTEPH is explicable. In general, exercising PAH patients
exhibit a limited increase in stroke volume due to sys-
tolic and diastolic impairment, increased RV afterload
and impaired ventriculoarterial coupling [38], while the
diastolic pressure–volume relationship determines filling
and CO [39]. In CTEPH the chronic obstructions in the
pulmonary circulation lead to an increase in RV after-
load and eventually to an impairment in RV function
[40] such that the increase in CO is compensatory
achieved through increases in HR. The disproportionate,
albeit enhanced ΔHR at baseline inside a cohort with an
overall impaired HRR, may reflect the severity of the
disease. One can speculate that an enhanced HRR at
baseline was mainly mirroring the inadequate response
of the RV to adapt to higher load during exercise with a
further impaired overall RV function and advanced RV
remodeling. Therefore, HRR was associated with the
hemodynamic outcome 1 year post-PEA in patients that
were less prone to RV reverse remodeling. PEA immedi-
ately reverses the increased RV afterload in CTEPH pa-
tients, while the magnitude of reverse RV remodeling
after PEA has been shown to correlate with changes in
hemodynamics, restoration of ventriculoarterial coupling
or reduction of RV systolic wall stress [33, 40–43]. How-
ever, it has been proposed that RV remodeling is only
partly reversible because of diffuse myocardial fibrosis
and differed individually [40]. As previously reported, re-
gression of concentric hypertrophy and restoration of
full right and left systolic function assessed by means of
Cardiac Magnetic Resonance Imaging (cMRI) require a
longer period of time of up to several years [43].
Interestingly, the ΔHR and the HRR during CPET
failed as prognostic marker in our cohort, highlighting
the value of 6MWT in CTEPH. Being a self-paced sub-
maximal effort test, it results in an aerobic steady-state,
as opposed to CPET which is a maximal effort test. Thus
differences in HRR with increased HR in more severely
ill patients, as discussed above, may be observed in this
test, but not at maximal effort. We therefore speculate
that ΔHR and the HRR assessed during 6MWT are
superior in reflecting disease severity in a selected cohort
of operable CTEPH patients. As shown previously, differ-
ences of the cardiac, ventilatory and metabolic response
during 6MWT in comparison with CPET in patients with
PAH are occurring [15, 44]. CPET is associated with higher
a minute ventilation, respiratory exchange ratio and max-
imal HR in comparison with 6MWT [44]. Therefore,
Deboeck and coworkers concluded that 6MWT is a
more realistic test for the determination of the exercise
capacity than CPET and is more reflective of therapeutic
interventions [44].
Limitations of the study are the small sample size and
highly selected patient sample that excluded patients
with obstructive pulmonary diseases. As we are a na-
tional referral center, the 1 year follow-up visit was not
Fig. 3 Associations between baseline Δ HR and PVR (r = 0.43, p = 0.01)
(a) and mPAP (r = 0.21, p = 0.23) (b) 1 year post-PEA. For abbreviations
see Table 1
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mandatorily performed in our center and accounts for
the dropout rate of 26 patients. Furthermore, 31 patients
refused participation at the time of screening due to
various reasons. Taking together this drop out rate pro-
duces potential bias. In addition, since the rate of re-
sidual PH was higher than reported in the literature, a
selection bias is possible. To confirm and elucidate the
pathophysiological findings of our study, larger prospect-
ive studies including post-procedural cMRI and angiog-
raphies for quantification of reverse remodeling and
residual perfusion impairments will be necessary.
Conclusions
This is the first prospective study to describe an association
of additional characteristics derived from 6MWT with the
hemodynamic outcome 1 year post-PEA in a selected co-
hort of operable CTEPH patients. Our preliminary results
indicate that ΔHR and HRR assessed during 6MWT are of
clinical value in patients with operable CTEPH, and HRR
during 6MWT may serve as a predictor of residual PH.
EID was commonly observed in operable CTEPH, albeit
failed as a significant prognostic factor.
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6MWD: six-minute walking distance; 6MWT: six-minute walking test;
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